The effect of acetylcysteine and bromhexine on the improvement and prevention of hospitalization in outpatients with Covid-19

Evaluation of the efficacy of N-acetylcysteine and Bromhexine compared with Standard Care in Preventing Hospitalization of Outpatients with COVID-19: A double-blind randomized clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220302054167N1

Enrollment

225

Registered

2022-04-29

Start date

2022-03-10

Completion date

Unknown

Last updated

2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

covid-19. COVID-19, virus identified

Interventions

Intervention 1: Intervention group: The first group was a group of patients taking oral acetylcysteine(Hakim company) 600 mg twice daily for 5 days. Intervention 2: Intervention group: The second meth

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Outpatients with Covid-19 symptoms after positive Covid-19 RT-PCR test Oxygen level 98-92%

Exclusion criteria

Exclusion criteria: • Dissatisfaction of the patient or their relatives to participate in the study • Pregnancy and lactation Evidence of pulmonary involvement and the need for hospitalization or referral to an infectious disease specialist Prohibition of N-acetylcysteine and bromhexine as a history of allergy and anaphylactic shock

Design outcomes

Primary

Measure	Time frame
Blood Oxygen. Timepoint: At the beginning of the study (before the intervention) and 7, 14 days. Method of measurement: pulse oximeter.;Cough. Timepoint: At the beginning of the study (before the intervention) and 7, 14 days. Method of measurement: questionnaire.;Shortness of breath. Timepoint: At the beginning of the study (before the intervention) and 7, 14 days. Method of measurement: questionnaire.;Sore throat. Timepoint: At the beginning of the study (before the intervention) and 7, 14 days. Method of measurement: questionnaire.	—

Measure

Time frame

Blood Oxygen. Timepoint: At the beginning of the study (before the intervention) and 7, 14 days. Method of measurement: pulse oximeter.;Cough. Timepoint: At the beginning of the study (before the intervention) and 7, 14 days. Method of measurement: questionnaire.;Shortness of breath. Timepoint: At the beginning of the study (before the intervention) and 7, 14 days. Method of measurement: questionnaire.;Sore throat. Timepoint: At the beginning of the study (before the intervention) and 7, 14 days. Method of measurement: questionnaire.

—

Secondary

Measure	Time frame
Time to recover from the desired symptoms. Timepoint: daily. Method of measurement: questionnaire.;Duration of hospitalization. Timepoint: At the beginning of the study (before the intervention) and 7, 14 days. Method of measurement: questionnaire.;Death. Timepoint: At the beginning of the study (before the intervention) and 7, 14 days. Method of measurement: questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAnahita Eslami-Ghayour

Hamedan University of Medical Sciences

anahitaeslami1995@gmail.com+98 81 3824 5383

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 9, 2026